NewsFeed Voices Science Insight Innovation
Ben Derman: One Recommendation I Make Over and Over is to Use a Prophylactic DOAC Instead of Aspirin
Ben Derman/X
Nov 1, 2025, 02:14

Ben Derman: One Recommendation I Make Over and Over is to Use a Prophylactic DOAC Instead of Aspirin

Ben Derman, Asst Professor at University of Chicago, posted on X:

“One recommendation I make over and over is to use a prophylactic DOAC instead of aspirin in newly diagnosed myeloma. Just choose a DOAC [they are getting much more affordable!]!
Risk scores lack validation for choosing VTE ppx.
The BENEFIT trial shows 6-month incidence of VTE was 0.8% in patients receiving ppx DOAC vs 5.6% with ppx heparin, and 9.8% in patients receiving aspirin.”

Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial

Authors:Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet-Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu

Ben Derman: One Recommendation I Make Over and Over is to Use a Prophylactic DOAC Instead of Aspirin

Read full article here.

Stay informed with Hemostasis Today.

Arthur Bobin Aurore Perrot Bernard Tardy Corinne Frere Cyrille Hulin Cyrille Touzeau Elisabeth Daguenet Emilie Chalayer Hervé Avet–Loiseau Ilhame Bounouara Jill Corre Karim Belhadj Laurent Frenzel Lionel Karlin Manon Sapet Margaret Macro Mohamad Mohty Olivier Decaux Philippe Moreau Salomon Manier Stephanie Harel Thierry Facon Thomas Lecompte Xavier Leleu
NewsFeed